Advanced Therapy Medicinal Products (ATMPs) promise transformative treatments for conditions that have long resisted conventional approaches. But that promise comes with a development pathway unlike anything seen with small molecules or biologics. ATMPs behave differently, are regulated differently, and require a development strategy built around their biology rather than borrowed from other modalities.
For emerging biotechs, this can feel overwhelming.
For emerging biotechs, this can feel overwhelming. The science is cutting edge, the regulatory expectations are evolving, and the traditional rules doesn’t always apply. But with the right structure — and the right partners — ATMP development becomes far more predictable than it first appears.
The ATMP development playbook outlines the essential steps sponsors need to take to move an ATMP from early research into first in human studies with clarity and confidence. Start with a risk-based mindset.
Unlike traditional therapeutics, ATMPs don’t follow a single, prescriptive set of nonclinical requirements. Regulators expect developers to build their programmes around a risk-based assessment: identifying the specific risks inherent to the product and designing studies that address them directly.
That means understanding:
how the product behaves in the body;
what could go wrong (e.g., immunogenicity, tumourigenicity, off target effects, shedding, biodistribution);
what needs to be demonstrated before first in human dosing.
A strong risk assessment becomes the backbone of the entire development plan. It determines which non clinical studies are essential, which models are appropriate, and where alternative methods — such as organoids or in vitro systems — may be acceptable.
ATMPs rarely fit neatly into conventional in-vitro or animal models. Their mechanisms of action, microenvironments, and immunological interactions often require customized approaches. Effective nonclinical programmes typically involve: clinical programmes typically involve:
carefully chosen models that reflect human biology as closely as possible;
targeted studies that answer specific risk questions;
early development of potency assays linked to mechanism of action;
thoughtful biodistribution and shedding assessments;
The goal isn’t to tick boxes — it’s to generate data that genuinely predicts human behaviour. Sponsors who embrace this mindset early avoid unnecessary studies and build a stronger case for clinical entry.
ATMP manufacturing is as much a part of the product as the therapeutic concept itself. Variability in starting materials, donor derived components, and manufacturing processes can all influence safety and efficacy. Early CMC planning should include: defining critical quality attributes;
establishing robust, reproducible manufacturing steps;
ensuring traceability across the entire process;
planning for comparability as processes evolve.
Sponsors who treat CMC as a strategic pillar — not an afterthought — are far better positioned to progress smoothly through regulatory review and into clinical development.
ATMPs often show substantial variability between patients, influenced by disease state, prior treatments, and biological factors. Clinical plans must account for this from the outset. Key considerations include:
selecting appropriate patient populations;
designing dose escalation strategies that reflect biological activity; preparing for long-term safety follow-up;
ensuring investigators are trained in ATMP specific administration and monitoring; building clear causality frameworks for adverse events.
A well-structured clinical plan anticipates these complexities rather than reacting to them. Create a development plan that investors and regulators can trust.
A strong Product Development Plan (PDP) ties everything together. It outlines the scientific rationale, non-clinical strategy, CMC roadmap, clinical design, regulatory interactions, timelines, and costs — all grounded in the risk-based assessment. For early-stage companies, a clear PDP is often the difference between securing funding and postponing the study. It demonstrates that the programme is thought through, the risks are understood, and the path to first-in-human is realistic.
ATMP development touches every discipline: non-clinical science, CMC, clinical pharmacology, regulatory strategy, and operational delivery.
ATMP development touches every discipline: non-clinical science, CMC, clinical pharmacology, regulatory strategy, and operational delivery. When these functions operate in isolation, gaps appear — and gaps in ATMP development become delays, redesigns, or regulatory pushback
For ATMP sponsors, that integration is invaluable. It reduces uncertainty, strengthens submissions, and creates a smoother, more predictable path from concept to clinic.
ATMPs demand a development strategy built around their biology, their risks, and their long-term implications. Sponsors who embrace a risk-based approach, invest early in CMC and non-clinical design, and build a coherent development plan move faster and with greater confidence